LBX(SH:603883) Chang Sha Wan Bao·2025-10-28 12:39Core Insights - The company reported a revenue of 5.296 billion yuan for Q3 2025, with a year-on-year growth of 0.07%, and a net profit of 131 million yuan, reflecting a year-on-year increase of 2.62%, indicating a recovery in performance [1] - The company announced a mid-term dividend plan for 2025, proposing a cash dividend of 0.14 yuan per share, totaling 106 million yuan, which contributes to a cumulative cash dividend of 2.175 billion yuan since its IPO, enhancing investor returns [1] - The company is undergoing a "dual-line" transformation, shifting from "transaction-based" to "relationship-based" stores, and from "sitting merchants" to "traveling merchants" [2] Financial Performance - In the first three quarters of 2025, the company's cumulative revenue exceeded 16.07 billion yuan, with a net profit of 529 million yuan [1] - The company's online sales reached approximately 2.23 billion yuan in the first three quarters, marking a year-on-year growth of 28% [2] Strategic Initiatives - The company is focusing on enhancing its supply chain collaboration, with a centralized procurement ratio of 75.2% in the first three quarters, an increase of 3.9 percentage points year-on-year [2] - The company has implemented an AI-driven approach to improve operational efficiency, with the "Old Hundred's Little Maruko AI" 2.0 version covering key business scenarios [2] Industry Context - The industry is experiencing accelerated consolidation and differentiation due to stricter healthcare regulations and intensified competition, with a net decrease of 3,395 pharmacies in Q4 2024 and 4,002 in Q1 2025 [3] - As of September 30, the company operates 15,492 stores across 18 provincial markets, positioning itself favorably amidst industry challenges [3]